RB1 and cancer: Interestingly, increased E2F activity is an expected feature of SCLC due to the recurrent loss of the negative regulator RB1 in this cancer [3]; and we were able to confirm this phenotype in our own RB1 knockdown models (shown in Fig. 4B).